Peter Weinstein
CEO Circurna
Peter D. Weinstein, Ph.D., J.D., is the CEO of Circurna, Inc., bringing over 30 years of experience across biotech business, law, R&D, intellectual property, and fundraising. He began as a scientist with a Ph.D. from the University of Pennsylvania and held research fellowships at the NIH and USAMRIID before transitioning to law, where he worked at the USPTO and top firms including Goodwin Procter and Fish & Richardson. As head of Baxter’s hemophilia programs, he built patent portfolios that generated hundreds of millions in licensing revenue and helped lead two therapies—Adenovate® and Vonvendi®—from bench to FDA/EMEA approval. He later founded Entralta, a boutique legal and business consultancy that served over 350 startups and small companies. Dr. Weinstein’s unique blend of scientific, legal, and business expertise enables Circurna to advance toward clinical milestones rapidly and cost-effectively.
Seminars
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
- Showcasing the development of a circular RNA platform that is room temperature stable, durable for a long period of time in vivo after administration and results in very high protein production starting shortly after administration
- Administrating circular RNA using microneedle patches resulting in preferential targeting of the circular RNA to the cells that produce protein in vivo to treat cancers, autoimmune, fibrosis and other diseases and will be used on human patients as part of Circurna’s first Phase I clinical trial in early 2027
- Developing a novel and industry leading purification manufacturing protocol that results in high circularization, high yield, high purity at a low cost
